J.P. Morgan’s healthcare analyst Cory Kasimov came out today with an update on Ziopharm Oncology Inc (NASDAQ:ZIOP), as the company’s breakout session is wrapping up at the 2015 J.P. Morgan Healthcare Conference. The analyst has a Neutral rating on the stock, while no price target was provided.
Kasimov noted, “Dr. Jonathan Lewis (CEO of ZIOP), Dr. Gregory Frost (XON), and Dr. Laurence Cooper (MD Anderson) all participated in the presentation and Q&A, which provided an overview of the technologies that will be combined under the recently announced collaboration in the CAR-T space.” He continued, “though we note the ZIOP story has “changed overnight,” and we acknowledge the potential in the CAR-T space. That said, we await further clarity on how these technologies will come together/the clinical profile of the ZIOP/XON products before becoming more constructive on the name.”
The analyst added, “When asked about the existing clinical data in the CD19 space from his CAR-T program (which has so far shown lower efficacy vs. competitors) Dr. Cooper noted that in his mind the initial focus was on safety, and using the ZIOP/XON technology, he can now build on efficacy.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 12.3% and a 56.1% success rate. Kasimov is ranked #511 out of 3426 analysts.